145 phenotypes from 8 alleles in 17 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
B9d2/Tgfb1tm1Flv/B9d2/Tgfb1tm1Flv Tg(Cd4-cre)1Cwi/0 involves: 129S6/SvEvTac * C57BL/6 * SJL	abnormal regulatory T cell physiology	J:204761
B9d2/Tgfb1tm1Flv/B9d2/Tgfb1tm1Flv Tg(CD207-cre)1Dhka/? involves: 129S6/SvEvTac * C57BL/6J * SJL/J	decreased Langerhans cell number	J:126147
B9d2/Tgfb1tm1Flv/Tgfb1tm2Flv Foxp3tm4(YFP/icre)Ayr/Foxp3+ involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ	normal growth/size/body region phenotype	J:169839
	normal immune system phenotype	J:169839
	increased regulatory T cell number	J:169839
B9d2/Tgfb1tm1Flv/Tgfb1tm2Flv Tg(Cd4-cre)1Cwi/0 involves: 129S6/SvEvTac * C57BL/6 * DBA/2	abnormal colon morphology	J:123547
	abnormal crypts of Lieberkuhn morphology	J:123547
	abnormal hepatocyte morphology	J:123547
	abnormal inflammatory response	J:123547
	abnormal interferon level	J:123547
	abnormal interleukin level	J:123547
	abnormal intestinal epithelium morphology	J:123547
	abnormal lung morphology	J:123547
	abnormal T cell activation	J:123547
	abnormal T cell differentiation	J:123547
	abnormal T-helper 17 cell differentiation	J:169839
	cachexia	J:123547
	colitis	J:123547
	crypts of Lieberkuhn abscesses	J:123547
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:123547
	diarrhea	J:123547
	increased anti-double stranded DNA antibody level	J:123547
	increased anti-nuclear antigen antibody level	J:123547
	increased T cell proliferation	J:123547
	premature death	J:123547
	renal glomerular immunoglobulin deposits	J:123547
B9d2/Tgfb1tm1Flv/Tgfb1tm2Flv Tnfrsf4tm2(cre)Nik/Tnfrsf4+ involves: 129S6/SvEvTac * 129X1/SvJ	abnormal enterocyte proliferation	J:169839
	abnormal T cell differentiation	J:169839
	cachexia	J:169839
	colitis	J:169839
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:169839
	decreased T-helper 17 cell number	J:169839
	increased regulatory T cell number	J:169839
	increased T-helper 1 cell number	J:169839
	liver inflammation	J:169839
	lung inflammation	J:169839
Tg(Lck-cre)548Jxm/? Tgfb1tm2.1Doe/Tgfb1tm2.1Doe involves: 129S6/SvEvTac * Black Swiss * C57BL/6 * CBA	abnormal immune system organ morphology	J:150024
	abnormal T cell activation	J:150024
	abnormal T cell subpopulation ratio	J:150024
	decreased spleen weight	J:150024
	decreased thymus weight	J:150024
	increased inflammatory response	J:150024
	increased interferon-gamma secretion	J:150024
	increased interleukin-2 secretion	J:150024
	lung inflammation	J:150024
	salivary gland inflammation	J:150024
	spleen hypoplasia	J:150024
	thymus hypoplasia	J:150024
	weight loss	J:150024
Tgfb1tm1(Tgfb3)Kul/Tgfb1tm1(Tgfb3)Kul involves: 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal bone ossification	J:204892
	abnormal enamel morphology	J:204892
	abnormal incisor color	J:204892
	abnormal incisor morphology	J:204892
	abnormal T cell morphology	J:204892
	abnormal tooth attrition	J:204892
	abnormal tooth mineralization	J:204892
	abnormal tooth morphology	J:204892
	ameloblast degeneration	J:204892
	normal craniofacial phenotype	J:204892
	decreased body height	J:204892
	decreased body weight	J:204892
	decreased circulating insulin level	J:204892
	decreased circulating leptin level	J:204892
	decreased osteoblast cell number	J:204892
	decreased subcutaneous adipose tissue amount	J:204892
	decreased total body fat amount	J:204892
	decreased white fat cell size	J:204892
	normal immune system phenotype	J:204892
	improved glucose tolerance	J:204892
	increased food intake	J:204892
	increased monocyte cell number	J:204892
	increased regulatory T cell number	J:204892
	infertility	J:204892
	kyphosis	J:204892
	malocclusion	J:204892
	misaligned incisors	J:204892
	normal mortality/aging	J:204892
	premature death	J:204892
Tgfb1tm1Doe/Tgfb1+ involves: 129S2/SvPas * CF-1	abnormal physiological response to xenobiotic	J:137529
	increased circulating creatinine level	J:137529
	increased susceptibility to kidney reperfusion injury	J:137529
	renal tubular necrosis	J:137529
Tgfb1tm1Doe/Tgfb1tm1Doe C.129S2-Tgfb1tm1Doe	decreased CD4-positive, alpha-beta T cell number	J:69346
	heart inflammation	J:69346
	hepatic necrosis	J:69346
	increased CD4-positive, alpha-beta T cell number	J:69346
	increased circulating alanine transaminase level	J:69346
	increased interferon-gamma secretion	J:69346
	increased T-helper 1 cell number	J:69346
	liver inflammation	J:69346
	postnatal lethality, incomplete penetrance	J:69346
	prenatal lethality, incomplete penetrance	J:69346
Tgfb1tm1Doe/Tgfb1tm1Doe involves: 129S2/SvPas	normal nervous system phenotype	J:117465
Tgfb1tm1Doe/Tgfb1tm1Doe involves: 129S2/SvPas * BALB/c * CF-1	heart inflammation	J:69346
	increased circulating alanine transaminase level	J:69346
	increased interferon-gamma secretion	J:69346
	liver inflammation	J:69346
	normal liver/biliary system phenotype	J:69346
	lung inflammation	J:69346
	postnatal lethality, complete penetrance	J:69346
	prenatal lethality, incomplete penetrance	J:69346
Tgfb1tm1Doe/Tgfb1tm1Doe involves: 129S2/SvPas * CF-1	abnormal diaphragm morphology	J:2892
	abnormal inflammatory response	J:2892
	abnormal Peyer's patch germinal center morphology	J:2892
	brain inflammation	J:2892
	cachexia	J:2892
	conjunctivitis	J:2892
	decreased Peyer's patch number	J:2892
	diaphragmitis	J:2892
	disheveled coat	J:2892
	enlarged lymph nodes	J:2892
	eye inflammation	J:2892
	gastric necrosis	J:2892
	gastric ulcer	J:2892
	heart inflammation	J:2892
	normal homeostasis/metabolism phenotype	J:2892
	hunched posture	J:2892
	increased leukocyte cell number	J:2892
	lacrimal gland inflammation	J:2892
	lethality at weaning, complete penetrance	J:2892, J:99033
	liver inflammation	J:2892
	lung inflammation	J:2892
	multifocal hepatic necrosis	J:2892
	myocardium necrosis	J:2892
	myositis	J:2892
	pancreas inflammation	J:2892
	salivary gland inflammation	J:2892
	skin inflammation	J:2892
	small spleen	J:2892
	stomach inflammation	J:2892
Tgfb1tm1Doe/Tgfb1tm2.1Doe Tg(Lck-cre)548Jxm/? involves: 129S2/SvPas * 129S6/SvEvTac * Black Swiss * BALB/c * C57BL/6 * CBA	lung inflammation	J:150024
	salivary gland inflammation	J:150024
Tgfb1tm1N/Tgfb1+ involves: 129S/SvEv * C57BL/6J * NIH/Ola	embryonic lethality during organogenesis, incomplete penetrance	J:26913
Tgfb1tm1N/Tgfb1tm1N involves: 129S/SvEv	abnormal atrial thrombosis	J:50848
	abnormal immune system physiology	J:120085
	abnormal liver morphology	J:120085
	abnormal lung morphology	J:120085
	absent Langerhans cell	J:120085
	atrial endocarditis	J:50848
	cachexia	J:50848
	colonic necrosis	J:50848
	disheveled coat	J:50848
	gastric necrosis	J:50848
	increased inflammatory response	J:50848
	interstitial pneumonia	J:50848
	lymph node inflammation	J:50848
	myocarditis	J:50848
	pancreas inflammation	J:50848
	pericarditis	J:50848
	phlebitis	J:50848
	premature death	J:50848
	prenatal lethality, incomplete penetrance	J:50848
	salivary gland inflammation	J:50848
Tgfb1tm1N/Tgfb1tm1N involves: 129S/SvEv * C57BL/6J * NIH/Ola	abnormal embryonic erythropoiesis	J:26913
	abnormal embryonic hematopoiesis	J:26913
	abnormal extraembryonic tissue morphology	J:26913
	abnormal heart development	J:26913
	abnormal vascular endothelial cell differentiation	J:26913
	abnormal vitelline vasculature morphology	J:26913
	absent vitelline blood vessels	J:26913
	delayed hepatic development	J:26913
	edema	J:26913
	embryo tissue necrosis	J:26913
	embryonic growth retardation	J:26913
	embryonic lethality during organogenesis, incomplete penetrance	J:26913
	failure of chorioallantoic fusion	J:26913
	lethality throughout fetal growth and development, incomplete penetrance	J:26913
	open neural tube	J:26913
	pale yolk sac	J:26913
	postnatal lethality	J:68448
	postnatal lethality, incomplete penetrance	J:26913
Tgfb1tm1Rif/Tgfb1tm1Rif either: (involves: 129) or (involves: 129S/SvEv * C57BL/6)	abnormal enterocyte morphology	J:142353
	absent Langerhans cell	J:142353
	cecum inflammation	J:142353
	decreased body weight	J:142353
	heart inflammation	J:142353
	increased anal adenocarcinoma incidence	J:142353
	increased colon adenocarcinoma incidence	J:142353
	increased gastric adenocarcinoma incidence	J:142353
	increased inflammatory response	J:142353
	increased large intestine adenocarcinoma incidence	J:142353
	increased rectum adenocarcinoma incidence	J:142353
	increased stomach tumor incidence	J:142353
	increased tumor incidence	J:142353
	large intestinal inflammation	J:142353
	lung inflammation	J:142353
	premature death	J:142353
	proctitis	J:142353
	small intestinal inflammation	J:142353
	stomach inflammation	J:142353
Tgfb1tm1Rif/Tgfb1tm1Rif Not Specified	abnormal immune system physiology	J:141786
Tgfb1tm2Flv/B9d2/Tgfb1tm1Flv Tg(CD207-cre)1Dhka/? involves: 129S6/SvEvTac * C57BL/6J * SJL/J	decreased Langerhans cell number	J:126147
Tgfb1tm3.1Flv/Tgfb1tm3.1Flv Tg(Cd4-cre)1Cwi/0 involves: 129 * C57BL/6 * DBA/2 * NOD	increased regulatory T cell number	J:196160
	increased T-helper 1 cell number	J:196160